Company Overview and News

31
Trade War Hits Trump Heartland as China Targets Farms, Mines - Bloomberg

2018-06-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CQP BF.B CGHLY BF.A LNG BFA DDAIF CGHOF 0384

0
HK stocks fall ahead of next week's Trump-Kim summit, Fed meeting

2018-06-08 theedgemarkets
SHANGHAI (June 8): Hong Kong stocks fell the most in two weeks on Friday, as investors braced for a series of market-moving events next week including the US-North Korea summit and the Federal Reserve's policy meeting.
SWRAY CRWOY SWRBY 0390 CGHLY CRWOF SWRBF SWRAF CGHOF 0384 1099

2
China Harmonizes Booming Gas Market With Residential Price Hike - Bloomberg

2018-05-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CGHLY CGASY DSECF 8601 DSEEY CGHOF 0384

0
After winter gas crunch, China pumps for underground storage

2018-04-12 themalaymailonline
A security guard stands at the entrance of Xiangguosi underground gas storage run by PetroChina in Chongqing, China March 18, 2018. Picture taken March 18, 2018. — Reuters picCHONGQING (China), April 12 — On one of the many mountains in southwest China’s sprawling region of Chongqing, a dozen wells in an exhausted gas field are this week starting to take in fresh fuel piped in from Central Asia’s Turkmenistan, thousands of miles away.
CGHLY CGHOF 0384

14
A $2.3 Billion Manager Walls Off Politics and Beats 98% of Peers - Bloomberg

2018-04-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BAP CGHLY 0700 CGHOF 0384

0
Directors take advantage of share price increases on Hong Kong stock exchange to reduce stakes

2018-03-18 scmp
Selling among directors rose for the second straight week to HK$60 million in 34 firms compared with HK$57.5 million in 29 firms the previous week
CGHLY RKGXY RKGXF 1098 DAHCY CGHOF DAHCF 0384

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 006460794